Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 2.25
ALIM's Cash to Debt is ranked higher than
69% of the 1153 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. ALIM: 2.25 )
ALIM' s 10-Year Cash to Debt Range
Min: 0.32   Max: 508.46
Current: 2.25

0.32
508.46
Equity to Asset 0.45
ALIM's Equity to Asset is ranked higher than
57% of the 957 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. ALIM: 0.45 )
ALIM' s 10-Year Equity to Asset Range
Min: -0.25   Max: 0.45
Current: 0.45

-0.25
0.45
F-Score: 4
Z-Score: -2.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -391.16
ALIM's Operating margin (%) is ranked lower than
55% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.08 vs. ALIM: -391.16 )
ALIM' s 10-Year Operating margin (%) Range
Min: -1837.82   Max: -391.16
Current: -391.16

-1837.82
-391.16
Net-margin (%) -426.33
ALIM's Net-margin (%) is ranked lower than
54% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.34 vs. ALIM: -426.33 )
ALIM' s 10-Year Net-margin (%) Range
Min: -2469.5   Max: -426.33
Current: -426.33

-2469.5
-426.33
ROE (%) -232.80
ALIM's ROE (%) is ranked lower than
57% of the 1128 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.08 vs. ALIM: -232.80 )
ALIM' s 10-Year ROE (%) Range
Min: -270.19   Max: -61.59
Current: -232.8

-270.19
-61.59
ROA (%) -56.39
ALIM's ROA (%) is ranked lower than
55% of the 1163 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.54 vs. ALIM: -56.39 )
ALIM' s 10-Year ROA (%) Range
Min: -329.68   Max: -20.46
Current: -56.39

-329.68
-20.46
ROC (Joel Greenblatt) (%) -1351.51
ALIM's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 1158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.77 vs. ALIM: -1351.51 )
ALIM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14172.99   Max: -1226.39
Current: -1351.51

-14172.99
-1226.39
EBITDA Growth (3Y)(%) 6.40
ALIM's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. ALIM: 6.40 )
ALIM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 13.3
Current: 6.4

0
13.3
EPS Growth (3Y)(%) 8.10
ALIM's EPS Growth (3Y)(%) is ranked higher than
77% of the 813 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. ALIM: 8.10 )
ALIM' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 19.5
Current: 8.1

0
19.5
» ALIM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ALIM Guru Trades in Q4 2013

Columbia Wanger 3,016,280 sh (unchged)
» More
Q1 2014

ALIM Guru Trades in Q1 2014

Columbia Wanger 3,016,280 sh (unchged)
Columbia Wanger 3,016,280 sh (unchged)
» More
Q2 2014

ALIM Guru Trades in Q2 2014

Columbia Wanger 1,168,298 sh (-61.27%)
» More
Q3 2014

ALIM Guru Trades in Q3 2014

Columbia Wanger Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ALIM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 24.03
ALIM's P/S is ranked lower than
69% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.25 vs. ALIM: 24.03 )
ALIM' s 10-Year P/S Range
Min: 21.86   Max: 512
Current: 24.03

21.86
512
EV-to-EBIT -7.90
ALIM's EV-to-EBIT is ranked higher than
61% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.16 vs. ALIM: -7.90 )
ALIM' s 10-Year EV-to-EBIT Range
Min: -8.7   Max: -2.2
Current: -7.9

-8.7
-2.2
Current Ratio 7.95
ALIM's Current Ratio is ranked higher than
92% of the 1023 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. ALIM: 7.95 )
ALIM' s 10-Year Current Ratio Range
Min: 0.59   Max: 8.76
Current: 7.95

0.59
8.76
Quick Ratio 7.78
ALIM's Quick Ratio is ranked higher than
93% of the 1023 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. ALIM: 7.78 )
ALIM' s 10-Year Quick Ratio Range
Min: 0.59   Max: 8.76
Current: 7.78

0.59
8.76
Days Inventory 393.86
ALIM's Days Inventory is ranked higher than
54% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 139.62 vs. ALIM: 393.86 )
ALIM' s 10-Year Days Inventory Range
Min: 245.39   Max: 445.49
Current: 393.86

245.39
445.49
Days Sales Outstanding 36.83
ALIM's Days Sales Outstanding is ranked higher than
92% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 89.57 vs. ALIM: 36.83 )
ALIM' s 10-Year Days Sales Outstanding Range
Min: 36.83   Max: 97.49
Current: 36.83

36.83
97.49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.20
ALIM's Price/Net Cash is ranked higher than
90% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ALIM: 13.20 )
ALIM' s 10-Year Price/Net Cash Range
Min: 1.37   Max: 14.58
Current: 13.2

1.37
14.58
Price/Median PS Value 0.60
ALIM's Price/Median PS Value is ranked higher than
97% of the 1277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. ALIM: 0.60 )
ALIM' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 1.82
Current: 0.6

0.61
1.82
Earnings Yield (Greenblatt) -12.80
ALIM's Earnings Yield (Greenblatt) is ranked lower than
59% of the 1150 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ALIM: -12.80 )
ALIM' s 10-Year Earnings Yield (Greenblatt) Range
Min: -14.8   Max: 0
Current: -12.8

-14.8
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:ASZ.Germany,
Alimera Sciences Inc is a Delaware corporation incorporated on June 4, 2003. The Company together with its subsidiaries is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Its only commercial product is ILUVIEN, which has received marketing authorization in Austria, the United Kingdom, Portugal, France, Germany and Spain, and has been recommended for marketing authorization in Italy, for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. ILUVIEN is the first product approved for chronic DME in the United Kingdom and European Union. ILUVIEN has not been approved by the U.S. Food and Drug Administration. ILUVIEN is an intravitreal implant providing a therapeutic effect for up to 36 months in the treatment of vision impairment associated with chronic DME by delivering sustained sub-microgram levels of FAc, a non-proprietary corticosteroid. Intravitreal refers to the space inside the eye behind the lens that contains the jelly-like substance called vitreous. DME is a disease of the retina which affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure using a sterile preloaded applicator employing a 25-gauge needle, which allows for a self-sealing wound. This procedure is very similar to the administration of an intravitreal injection, a procedure commonly employed by retinal specialists. The majority of its sales have been in Germany. The Company faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies. The manufacture and packaging of pharmaceutical products such as ILUVIEN are subject to the requirements of the FDA and similar foreign regulatory entities.
» More Articles for ALIM

Headlines

Articles On GuruFocus.com
comment on ALIM Mar 02 2013 
Alimera Sciences Inc. (ALIM) President and CEO C. Daniel Myers sells 45,523 Shares Mar 16 2011 
The Most Speculative Stocks on the Market: Harbinger, Kaching Kaching, Alimera Sciences, Star Scient Jul 29 2010 


More From Other Websites
Nasdaq stocks posting largest percentage increases Apr 17 2015
Alimera Sciences' ILUVIEN® Receives 17th European Marketing Authorization; Completing Second Wave... Apr 14 2015
How the bulls are playing Alimera Apr 14 2015
Alimera Sciences' ILUVIEN® Receives 17th European Marketing Authorization; Completing Second Wave... Apr 14 2015
Is Alimera Sciences (ALIM) Stock a Solid Choice Right Now? - Tale of the Tape Apr 13 2015
ALIMERA SCIENCES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Mar 25 2015
ALIMERA SCIENCES INC Financials Mar 20 2015
Alimera Sciences to Host Analyst and Investor Luncheon on Wednesday, March 25, 2015 in New York City Mar 19 2015
Alimera Sciences to Host Analyst and Investor Luncheon on Wednesday, March 25, 2015 in New York City Mar 19 2015
ALIMERA SCIENCES INC Files SEC form 10-K, Annual Report Mar 13 2015
ALIMERA SCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 09 2015
Alimera Sciences reports 4Q loss Mar 04 2015
Alimera Sciences reports 4Q loss Mar 04 2015
Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results Mar 04 2015
ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 04 2015
Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results Mar 04 2015
Q4 2014 Alimera Sciences Inc Earnings Release - After Market Close Mar 04 2015
Connecture Inc (CNXR), Hyperion Therapeutics Inc (HPTX): Top 5 Healthcare Picks of Great Point... Mar 02 2015
Alimera Sciences To Release Fourth Quarter And Fiscal Year 2014 Financial Results Feb 24 2015
Alimera Sciences To Present At 2015 Cowen Healthcare Conference Feb 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK